Related Experiment Video
Updated: May 9, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Net Benefit of Anticoagulation in Subclinical Device-Detected Atrial Fibrillation
Aleksi K Winstén1,2, Ville Langén3, K E Juhani Airaksinen4
1Department of Mathematics and Statistics, University of Turku, Turku, Finland.
Insights
For patients with device-detected subclinical atrial fibrillation (AF), nonvitamin K antagonist oral anticoagulants (NOACs) offer a small, uncertain benefit for stroke prevention. The overall net benefit in quality-adjusted life-years (QALYs) was minimal and not clinically significant.
Area of Science:
- Cardiology
- Medical Informatics
- Health Economics
Background:
- Subclinical atrial fibrillation (AF) detected by devices presents a dilemma for stroke prevention.
- The net benefit of anticoagulation in these patients remains uncertain.
Purpose of the Study:
- To assess the net benefit of nonvitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in patients with device-detected subclinical AF.
- To evaluate the impact of NOACs on quality-adjusted life-years (QALYs) and clinical outcomes.
Main Methods:
- A decision analytical model simulating 10,000 patients with and without NOACs over 10 years.
- Markov decision model incorporating stroke risk, bleeding risk, and mortality data.
- Probabilistic sensitivity analyses were conducted to assess the impact of treatment effect uncertainties.
Main Results:
- NOAC therapy was associated with a 21.7% reduction in ischemic strokes and a 1.1% reduction in deaths.
- However, NOACs increased major bleeding events by 37.3%.
- The net gain in QALYs was approximately 0.024 per patient over 10 years, indicating a minimal benefit.
Conclusions:
- Initiating NOACs in subclinical AF shows a minimal increase in QALYs, but the benefits are uncertain.
- The overall net benefit of NOACs in this population may not be clinically meaningful.
- Further research is needed to clarify the optimal management strategy for subclinical AF.
Importance:
The role of anticoagulation for stroke prevention in patients with device-detected atrial high-rate episodes, also known as subclinical atrial fibrillation (AF), is a subject of equipoise.
Objective:
To assess the net benefit of nonvitamin K antagonist oral anticoagulants (NOACs) in patients with device-detected subclinical AF.
Design, Setting, And Participants:
Decision analytical model run with 10 000 patients with anticoagulation and 10 000 patients without anticoagulation in a clinical scenario of deciding whether to start NOACs for stroke prevention in patients with subclinical AF. A Markov decision model was conducted on October 1, 2024, to estimate net outcomes of NOACs. The patients had stroke risk and bleeding risks similar to those of patients in randomized trials of anticoagulation in subclinical AF.
Exposure:
Anticoagulation was modeled to decrease the risk of ischemic stroke by 32% and increase the risk of major bleeding by 62%. In probabilistic sensitivity analyses, the 95% CIs for treatment effect sizes were also considered.
Main Outcomes And Measures:
The main outcome measure for overall net benefit was the cumulative quality-adjusted life-years (QALYs) during the simulation. The model considered the number and severity of ischemic strokes, hemorrhagic strokes, other intracranial bleeds, and extracranial bleeds, as well as the number of deaths during a 10-year simulation.
Results:
When comparing the 2 cohorts of 10 000 patients (mean age, 77 years; 3700 [37%] women), those receiving NOAC therapy had 233 fewer ischemic strokes (21.7%), 55 fewer deaths (1.1%), and 453 more major bleeding events (37.3%) over a 10-year simulation period. Per patient, these differences translated to approximately 1 additional quality-adjusted week of life (0.024 QALYs) with NOAC treatment during the 10-year simulation. When the 95% CIs of treatment effect sizes were considered in probabilistic sensitivity analysis, there was a 65.8% probability that NOAC treatment leads to more QALYs than withholding treatment.
Conclusions And Relevance:
In this analytical model study, initiating NOACs in patients with device-detected subclinical AF was associated with a minimal increase in QALYs. However, the benefits were uncertain, and the effect size of the overall net benefit does not appear to be clinically meaningful.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:16Clot Retraction and Fibrinolysis